CAMBRIDGE, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14, 2016, starting at 8:30 a.m. ET. This event will be available via webcast and conference call only.

During the virtual R&D Day, members of the Genocea leadership team and leading physicians will provide a comprehensive overview of lead product candidate GEN-003 for the treatment of genital herpes, which is expected to enter Phase 3 development in 2017, and share how the Company is applying its unique and proprietary T cell antigen identification platform, ATLAS™, to immuno-oncology and cancer vaccine development.

Webcast & Conference Call Information
A live webcast of the R&D Day can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

Interested participants and investors may also join the event by conference call by dialing (800) 708-4540 (domestic) or (847) 619-6397 (international) and referencing the conference ID 43927983.

About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.

For media: 	
Liz Bryan 	
Spectrum Science Communications, Inc.
O: 202-955-6222	
lbryan@spectrumscience.com 

For investors: 
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191 
jonathan.poole@genocea.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.